RESUMO
PURPOSE: Recombinant human erythropoietin (rHuEPO) is the standard of care for patients with chemotherapy-related anemia. Intravenous (IV) iron improves hemoglobin (Hb) response and decreases dosage requirements in patients with anemia of kidney disease, but its effect has not been studied in randomized trials in cancer patients. METHODS: This prospective, multicenter, open-label, randomized trial enrolled 157 patients with chemotherapy-related anemia (Hb Assuntos
Anemia/tratamento farmacológico
, Antineoplásicos/efeitos adversos
, Eritropoetina/uso terapêutico
, Complexo Ferro-Dextran/administração & dosagem
, Ferro/administração & dosagem
, Anormalidades Induzidas por Medicamentos
, Administração Oral
, Idoso
, Anemia/etiologia
, Feminino
, Humanos
, Infusões Intravenosas
, Masculino
, Pessoa de Meia-Idade
, Neoplasias/tratamento farmacológico
, Estudos Prospectivos
, Qualidade de Vida
, Proteínas Recombinantes